Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma
- To independently correlate the gene expression and promoter methylation profiles to
chemotherapy response in patients with advanced or metastatic melanoma treated with
carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603.
- To develop a predictive model of chemotherapy response utilizing integrated analysis of
gene expression and promoter methylation data.
- To evaluate whether the NER pathway haplotypes are associated with platinum drug
resistance and survival.
OUTLINE: This is a multicenter study.
Archived paraffin-embedded tissue samples are analyzed for gene expression and promoter
methylation profiles, and genes involved in the NER pathway.
Correlation between gene expression and promoter methylation profiles to chemotherapy response
Hussein A. Tawbi, MD, PhD
University of Pittsburgh